[The perspectives in obesity and type 2 diabetes therapy: the present and future of incretin therapy].
Shestakova. M V MV; Bashlykova. R O RO
Key Findings
- Tirzepatide is a dual GLP‑1/GIP receptor agonist that shows strong effects on both obesity and type 2 diabetes.
- Current mono‑agonists (liraglutide, dulaglutide, semaglutide) are effective, but dual agonists appear more potent.
- Research is moving toward triple‑ and tetra‑agonists that target multiple gastrointestinal hormones for even greater metabolic benefits.
Practical Outcomes
- For self‑experimenters, tirzepatide represents a next‑generation option that may offer better weight loss and glucose control than existing GLP‑1 drugs, but it is still prescription‑only and should be used under medical supervision. Keep an eye on emerging multi‑agonist compounds, as they could become future tools for metabolic optimization.
Summary
The paper says that drugs that mimic gut hormones, especially tirzepatide which hits two hormone receptors at once, are looking very promising for losing weight and controlling blood sugar in diabetes. It also mentions that even newer drugs that hit three or four gut hormone receptors are being developed and could be even more powerful.
Abstract
The rates of increase in the incidence of type 2 diabetes mellitus (T2DM) and obesity in the world are steadily increasing and exceed even the wildest forecasts, which forces specialists to seek, develop and implement more effective therapeutic methods for these two interrelated non-communicable pandemics. This article discusses promising areas in the pharmacotherapy of obesity and T2DM with an emphasis on the development of a class of incretin hormone receptor agonists. Monoagonists (liraglutide, dulaglutide, semaglutide) and dual incretin receptor agonists (tirzepatide), as well as triple- and tetra-agonists of gastrointestinal hormones currently under development, which are expected to be even more effective in the complex treatment of both type T2DM and obesity, are being discussed.
Study Information
pubmed
2025
2025-11-11T00:00:00.000Z
10.26442/00403660.2025.10.203366
30